Search | Clinical Trials Finder

Conditions: Breast Cancer, Angiogenesis
Interventions: Aspirin; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 95 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Acute Ischaemic Stroke, Transient Ischaemic Attack
Interventions: ticagrelor, Acetylsalicylic acid (ASA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 13,307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 115
States / cities: Montgomery, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 112 more

Conditions: Systemic Lupus Erythematosus
Interventions: extended release dipyridamole 200mg/aspirin 25mg, 81mg aspirin; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Stable Coronary Artery Disease
Interventions: Ticagrelor, Clopidogrel, Aspirin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more

Conditions: Acute Coronary Syndromes
Interventions: Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 4,614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 143
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more

Conditions: Preeclampsia
Interventions: Aspirin 81 mg Enteric Coated Tab - 1 tablet, Aspirin 81 mg Enteric Coated Tab - 2 tablets; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 14 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Colorectal Neoplasia
Interventions: Omeprazole, Aspirin; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Conditions: Healthy Subjects
Interventions: Acetylsalicyclic acid (Fast release Aspirin, BAY1019036), Acetaminophen (Tylenol extra strength), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 16 Years to 45 Years
Enrollment: 510 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Drugs, Investigational
Interventions: Acetylsalicylic acid (Fast release Aspirin, BAY1019036), Acetylsalicylic Acid (Aspirin, BAYE4465), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 16 Years to 45 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Austin, Texas • Salt Lake City, Utah

Conditions: Anterior Cruciate Ligament Injuries
Interventions: Opiate Sparing, Opiate Based; Drug
Lead sponsor: Campbell Clinic; Other
Eligibility: 14 Years to 85 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Common Cold, Pharyngitis, Fever, Congestion, Rhinorrhea, Cough, Sore-throat, Sore Throats Viral, Malaise, Headache, Runny Nose, Sneezing
Interventions: Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, Wintergreen Throat Spray and Placebo Tablet, Placebo Throat Spray and Placebo Tablet; Drug · Dietary Supplement · Other
Lead sponsor: Applied Biological Laboratories Inc; Other
Eligibility: 18 Years to 65 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Irvine, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more

Conditions: Multiple Sclerosis
Interventions: Aspirin 650mg Oral Capsule, Acetaminophen Tablet 650mg, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease, Myocardial Infarction
Interventions: Ticagrelor, ASA; Drug
Lead sponsor: Juan Badimon; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke
Interventions: Apixaban, Aspirin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 45 Years and older
Enrollment: 1,015 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 165
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 111 more

Conditions: Aspirin-Associated Gastric Ulcers
Interventions: PA32540; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions: PEGASYS, Hydroxyurea, Aspirin; Drug
Lead sponsor: Ronald Hoffman; Other
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 16
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Interventions: Aspirin 81 mg, Placebo oral tablet; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury
Interventions: medrol dosepak, HYDROcodone Oral Tablet; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Moderate Risk of CVD
Interventions: Aspirin (Acetylsalicylic acid, BAYE4465), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 55 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 73
States / cities: Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more

Conditions: Peripheral Arterial Disease
Interventions: Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cardiovascular Disease
Interventions: Active Clonidine, Placebo Clonidine, Active ASA, Placebo ASA; Drug
Lead sponsor: Hamilton Health Sciences Corporation; Other
Eligibility: 45 Years and older
Enrollment: 10,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Coronary Artery Disease
Interventions: Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Lynch Syndrome
Interventions: Atorvastatin 20mg, Atorvastatin 20mg AND Aspirin 325 mg; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Coronary Syndrome
Interventions: Ticagrelor + ASA + Bivalirudin, Clopidogrel + ASA + Bivalirudin; Drug
Lead sponsor: Juan J Badimon; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Aspirin (ASA) Therapy and Preeclampsia Prevention

A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy

Evaluate Onset of Action of a Fast Release Aspirin

Evaluate Analgesic Efficacy of Fast Release Aspirin

ACL-R Opioid Sparing Study

Alleviation of Common Cold Symptoms

Aspirin for Exercise in Multiple Sclerosis (ASPIRE)

Platelet Sub-study of the TWILIGHT Trial

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

PeriOperative ISchemic Evaluation-2 Trial

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

Antithrombotic Effects of Ticagrelor Versus Clopidogrel